Search Within

Brigitte Senechal

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Adult Leukemia (6)
  2. Center for Hematologic Malignancies (6)
  3. Department of Medicine (6)
  4. Hematologic Malignancies, Division of (6)
  5. Molecular Imaging and Therapy Service (6)
  6. Radiology, Department of (6)

More Groups

People
  1. Xiuyan Wang (4)
  2. Briana Cadzin (3)
  3. Devanjan Sikder (3)
  4. Isabelle Riviere (3)
  5. Jae Park (3)
  6. Jonathan Landa (3)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (2)
  4. 2019 (1)
Publications
  1. Blood (4)
  2. Cancer Immunology Research (1)
  3. New England Journal of Medicine (1)
Publishers
  1. American Society of Hematology (4)
  2. American Association for Cancer Research (1)
  3. Massachusetts Medical Society (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Devlin, S. M.; Valtis, Y. K.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E.; Liotta, K.; Yu, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • An ongoing pilot study of targeted radioimmunotherapy (131-I apamistamab) conditioning prior to CD19-targeted CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Hosszu, K.; Senechal, B.; Spross, J. A.; Mark, A.; Desai, A.; Cathcart, E. R.; Palomba, M. L.; Pandit-Taskar, N.
    Blood (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy
    Journal Article

    Smith, E. L.; Mailankody, S.; Staehr, M.; Wang, X.; Senechal, B.; Purdon, T. J.; Daniyan, A. F.; Geyer, M. B.; Goldberg, A. D.; Mead, E.; more...
    Cancer Immunology Research (2019)

    Fulltext@MSK | Save